ArticleAmerican journal of translational research2025
Effects of nedaplatin combined with paclitaxel liposomes or docetaxel on survival rate and biomarkers in patients with recurrent ovarian cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.Journal of cancer research and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effects of combining nedaplatin with paclitaxel liposomes or docetaxel on survival rates and biomarkers in patients with recurrent ovarian cancer (ROC).
methodsA retrospective analysis was carried out on the clinical data of 238 ROC patients treated at Baoji Traditional Chinese Medicine Hospital between February 2018 and February 2022. The patients were divided into a control group (n=103), which received nedaplatin combined with paclitaxel liposomes, and an observation group (n=135), receiving nedaplatin combined with docetaxel. The treatment efficacy, adverse reactions, tumor biomarkers (CA125, CEA, HE4, and AFP), and inflammatory markers (TNF-α, IL-6) before and after treatment were compared between the two groups. Patients were followed up for 2 years to observe progression-free survival (PFS), and Kaplan-Meier survival curves were plotted and Logrank tests were performed to evaluate the 2-year PFS differences.
resultsThere were no significant differences in overall clinical efficacy or remission rates between the two groups post-treatment (both P>0.05). Both groups showed significant reductions in tumor biomarkers and inflammatory markers after treatment compared with pre-treatment levels (all P<0.05), and the differences between the groups after treatment were not significant (all P>0.05). The incidence of adverse reactions was also similar between the groups (P>0.05). Multivariate Cox regression analysis identified the treatment regimen (P<0.001), FIGO stage (P=0.005), maximum diameter of recurrent lesions (P=0.001), number of recurrent lesions (P<0.001), post-treatment CA125 (P<0.001), and post-treatment HE4 (P<0.001) as independent prognostic factors for PFS.
conclusionsThe combination of nedaplatin with paclitaxel liposomes or docetaxel demonstrated comparable efficacy in ROC patients, effectively reducing tumor and inflammatory markers without increasing adverse reactions. Importantly, the combination of nedaplatin and docetaxel significantly improved PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.